BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23150202)

  • 1. Oligoclonal reconstitution masquerading as myeloma relapse.
    Chim CS; Chan EY
    Ann Hematol; 2013 Jun; 92(6):847-8. PubMed ID: 23150202
    [No Abstract]   [Full Text] [Related]  

  • 2. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
    Lemaire O; Attal M; Bourin P; Laroche M
    Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation.
    Witzens-Harig M; Waldherr R; Beimler J; Zeier M; Hansmann J; Ho AD; Goldschmidt H; Moehler T
    Ann Hematol; 2007 Dec; 86(12):927-30. PubMed ID: 17605010
    [No Abstract]   [Full Text] [Related]  

  • 4. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
    Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
    Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 6. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bulbar palsy in multiple myeloma.
    Chim CS; Ooi GC
    Haematologica; 2005 Dec; 90(12 Suppl):ECR42. PubMed ID: 16464757
    [No Abstract]   [Full Text] [Related]  

  • 8. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
    Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
    Hematol Oncol; 2012 Sep; 30(3):156-62. PubMed ID: 22028144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
    Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
    Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
    Chim CS; Choi PT; Lee WK
    Ann Hematol; 2013 Jun; 92(6):855-7. PubMed ID: 23183880
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple myeloma presenting as plasmacytoma of the base of the skull.
    Alegre A; Tomás JF; Pinilla I; Gil-Fernández JJ; Fernández-Rañada JM
    Am J Hematol; 1996 May; 52(1):60-1. PubMed ID: 8638614
    [No Abstract]   [Full Text] [Related]  

  • 13. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
    Tovar N; Fernández de Larrea C; Pedrosa F; Aróstegui JI; Cibeira MT; Rosiñol L; Elena M; Filella X; Yagüe J; Bladé J
    Ann Hematol; 2014 Jan; 93(1):107-11. PubMed ID: 24218189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloma presenting during pregnancy.
    Smith D; Stevens J; Quinn J; Cavenagh J; Ingram W; Yong K
    Hematol Oncol; 2014 Mar; 32(1):52-5. PubMed ID: 23996410
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
    Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
    Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression.
    Somers LJ; Shaw B; Lyn BE; McMillan AM; Mahendra P
    Clin Lab Haematol; 1998 Jun; 20(3):189-90. PubMed ID: 9681237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.